Intacept 25 Solution for Injection contains Etanercept 25 mg, a recombinant human tumor necrosis factor (TNF) receptor fusion protein that acts as a selective immunosuppressant by binding to TNF-alpha and TNF-beta, thereby inhibiting their interaction with cell surface TNF receptors. This mechanism helps reduce inflammation and halt disease progression in various autoimmune conditions. Intacept 25 is indicated for the treatment of moderate to severe rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. It is administered via subcutaneous injection, typically once or twice weekly, depending on the specific condition and patient response. Prior to initiation, patients should be screened for latent tuberculosis and other infections, as Etanercept may increase susceptibility to serious infections. Caution is advised in patients with a history of recurrent infections or demyelinating disorders. Common adverse effects include injection site reactions, upper respiratory tract infections, headache, and rash. Regular monitoring of blood counts and liver function tests is recommended during therapy. Intacept 25 should be used under strict medical supervision, with careful consideration of contraindications and potential drug interactions to ensure optimal therapeutic outcomes.